EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Using demographics of patients to inform treatment of shigellosis in England

Lewis C E Mason, Daniel Richardson, Hannah Charles, Ian Simms, Holly D Mitchell, Rohini Manuel, Gauri Godbole, Claire Jenkins, Kate S Baker

The Lancet Microbe · 2025-04 · 6 (4) · 101026

DOI: 10.1016/j.lanmic.2024.101026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Microbe, 2025-04. Verfasst von Lewis C E Mason und 8 weiteren Autor:innen. Beteiligte Einrichtung: NIHR HPRU in Gastrointestinal Infections, University of Liverpool, Liverpool, UK; Department of Clinical Infection, Microbiology and Immunology, Inst…. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Shigellosis, caused by bacteria of the genus Shigella, is a diarrhoeal disease transmitted by the faecal–oral route.1 Rapid increases in the prevalence of extensively drug-resistant (XDR) Shigella isolates—also known as triple-resistant due to resistance to fluoroquinolones, third-generation cephalosporins, and azithromycin—during the final quarter of 2021 and the first quarter of 2022 in Europe, Northern America, and Australia have highlighted the urgent need to develop new antimicrobials and vaccines targeting high-priority Shigella spp.

Autor:innen und Institutionen

  • NIHR HPRU in Gastrointestinal Infections, University of Liverpool, Liverpool, UK; Department of Clinical Infection, Microbiology and Immunology, Institute for Infection, Veterinary and Ecological Sciences, University of…
  • Brighton and Sussex Medical School, Brighton, UK; University Hospitals Sussex National Health Service University hospitals Sussex NHS Foundation Trust, Brighton, UK.
  • UK Health Security Agency, London, UK.
  • NIHR HPRU in Gastrointestinal Infections, University of Liverpool, Liverpool, UK; UK Health Security Agency, London, UK.
  • NIHR HPRU in Gastrointestinal Infections, University of Liverpool, Liverpool, UK; Department of Genetics, University of Cambridge, Cambridge CB23EH, UK. Electronic address: kb827@cam.ac.uk.

Förderung

  • NIHR

Zitieren

APA

Mason, L. C. E., Richardson, D., Charles, H., Simms, I., Mitchell, H. D., Manuel, R., Godbole, G., Jenkins, C., & Baker, K. S. (2025). Using demographics of patients to inform treatment of shigellosis in England. The Lancet Microbe, 6(4), 101026. https://doi.org/10.1016/j.lanmic.2024.101026

Vancouver

Mason LCE, Richardson D, Charles H, Simms I, Mitchell HD, Manuel R, et al. Using demographics of patients to inform treatment of shigellosis in England. The Lancet Microbe. 2025;6(4):101026. doi:10.1016/j.lanmic.2024.101026

BibTeX
@article{Mason2025,
  author = {Mason, Lewis C E and Richardson, Daniel and Charles, Hannah and Simms, Ian and Mitchell, Holly D and Manuel, Rohini and Godbole, Gauri and Jenkins, Claire and Baker, Kate S},
  title = {Using demographics of patients to inform treatment of shigellosis in England},
  journal = {The Lancet Microbe},
  year = {2025},
  volume = {6},
  number = {4},
  pages = {101026},
  doi = {10.1016/j.lanmic.2024.101026}
}
Kostenlos starten →